Loading
Life sciences · Journal article
Molecular Medicine · October 8, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Effective therapeutics for metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are urgently needed as their global prevalence continues to rise. Deficiency of the G-protein-coupled receptor GPR39 predisposes to obesity and hepatosteatosis, yet its hepatic functions and therapeutic potential remain poorly understood. This study investigated whether pharmacological activation of GPR39 protects against MASLD/MASH and promotes regression of established disease. The selective GPR39 agonist TM-N1324 was evaluated in diet-induced models of MASLD/MASH, including preventive and disease-regression settings. Systemic and liver-specific effects were assessed and hepatic pathway activation was examined. GPR39 dependency, sex dependency, and body-weight dependency were evaluated by comparing treatment effects across relevant experimental groups. TM-N1324 robustly protected against MASLD/MASH and promoted regression of established disease. Treatment improved features of the metabolic syndrome, including glucose tolerance, cholesterol metabolism, adiposity, and respiratory exchange ratio, consistent with a shift in whole-body substrate utilization toward fat, while maintaining favorable circulating triglyceride profiles. In the liver, TM-N1324 enhanced ERK1/2 signaling and SREBP2, increased hepatic VLDL levels, reduced hepatic triglycerides, and suppressed ApoB. TM-N1324 increased hepatic PARylation, and intact hepatocyte NAD+ metabolism was required for the liver-protective effects. Hepatic responses were mediated by GPR39 and were independent of sex and body weight. Pharmacological activation of GPR39 with TM-N1324 protects against MASLD/MASH, promotes regression of established disease, and improves key features of metabolic syndrome. These findings provide evidence that GPR39 is a therapeutically actionable target in MASLD/MASH and support further development of GPR39 agonism as a treatment strategy for metabolic liver disease.